Trending Now - Oral Minoxidil Shows Promising Results in Hair Loss Study

WHO:

Gizmodo - Veradermics is the pharmaceutical company behind the oral minoxidil formulation, codenamed VDPHL01.

Gizmodo - Maryanne Makredes Senna is a scientific advisor for Veradermics and an assistant professor of dermatology at Harvard Medical School.

STAT - Reid Waldman is the CEO of Veradermics.

WHAT:

Gizmodo - VDPHL01 passed all goals in a Phase II/III clinical trial.

Gizmodo - 79% of men taking a single 8.5 milligram dose of VDPHL01 daily experienced significant hair growth.

Gizmodo - 86% of men taking a twice-daily dose of VDPHL01 reported significant hair growth.

Gizmodo - Only 36% of the placebo group saw any hair growth.

STAT - Men taking VDPHL01 grew between 30 and 33 more hairs per square centimeter of scalp on average, compared to approximately seven additional hairs in the placebo group.

Gizmodo - The total rate of adverse events was similar between treatment and placebo groups, with around 5% experiencing peripheral edema.

WHERE:

Gizmodo - The trial involved over 500 men with mild or moderate pattern hair loss.

WHEN:

Gizmodo - The results come from part A of the company’s “302” trial, which lasted six months.

WHY:

Gizmodo - VDPHL01 aims to provide a non-hormonal treatment option for pattern hair loss, addressing the limitations of topical minoxidil.

HOW:

Gizmodo - The trial randomized participants to receive either a placebo, a single daily dose, or a twice-daily dose of VDPHL01.

(UPDATED April 28, 2026 01:30 UTC)

Veradermics has announced promising results from its Phase II/III clinical trial for VDPHL01, an oral formulation aimed at treating pattern hair loss. In the trial involving over 500 men, 79% of those taking a single daily dose and 86% of those on a twice-daily dose experienced significant hair growth, compared to just 36% in the placebo group. The trial, which lasted six months, showed that men taking VDPHL01 grew between 30 and 33 more hairs per square centimeter of scalp on average, with a similar rate of adverse events between the treatment and placebo groups.